Europe's medicines regulator has added an extremely rare nerve-damaging disorder, Guillain-Barré syndrome, as a possible side-effect of AstraZeneca's Covid-19 vaccine, regular safety updates from the watchdog showed on Wednesday.
The European Medicines Agency said a causal relationship between GBS and the AstraZeneca shot, known as Vaxzevria, was an "at least a reasonable possibility" after 833 cases of GBS were reported out of 592 million doses of the vaccine given worldwide by July 31.
The EMA categorised the side-effect as...